With continued identification of targetable immune checkpoints and development of CPIs, such as an anti-CTLA-4 antibody, further clinical trials were conducted that evaluated them in the setting of prostate cancer (Table 1). This evidence concerns the gene CTLA4 and prostate carcinoma.